BNGO Bionano Genomics, Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
BNGO Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Medical Instruments & Supplies
Current Price
Live
$1.62
Analyst Target
$7.5
+363.0%
Upside
52W High
$6.98
52W Low
$1.41
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$16.49M
P/E
N/A
ROE
-78.2%
Profit margin
-134.4%
Debt/Equity
0.35
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
65%
Analysis Accuracy
The company exhibits extremely weak fundamental health with a Piotroski F-Score of just 1/9, indicating severe financial distress. Despite positive revenue growth and improving earnings surprises recently, the firm remains deeply unprofitable with negative margins, negative ROE, and a collapsed market valuation. The stock has lost nearly all value over the past 3–5 years, and while analysts project a high target price, current fundamentals do not support such optimism. Valuation metrics like Price/Book and Price/Sales are low, but this reflects distress rather than value, given the lack of earnings and cash flow visibility.
Key Strengths
Revenue growth of 21.3% YoY shows commercial traction in the business
Recent quarterly earnings have beaten estimates 3 out of the last 4 quarters
Average earnings surprise over the last 4 quarters is +42.66%, signaling improving execution
Current ratio of 2.12 indicates short-term liquidity is manageable
Debt/Equity of 0.35 is relatively low, suggesting limited leverage risk
Key Risks
Piotroski F-Score of 1/9 signals critical financial weakness and high risk of operational failure
Profit margin of -134.36% and ROE of -78.22% reflect deep, ongoing unprofitability
No Altman Z-Score available, but negative earnings and ROE imply potential distress risk (<1.8 threshold)
Market cap of $0.02B and extreme price decline (-99.8% over 3Y) suggest market loss of confidence
Lack of cash flow, debt, and share count data limits financial transparency and increases investment risk
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
24
Weak
25
58
20
15
0
AI Verdict
High-risk speculative position with fragile fundamentals
Key drivers: Critically low Piotroski F-Score, Strong revenue growth and improving earnings surprises, Extremely negative profitability metrics, Analyst optimism not yet reflected in price or fundamentals, Liquidity concerns mitigated by current ratio but not profitability
Confidence
70%
Value
25/100
Ref P/E, PEG, Graham Number
Positives
- Low Price/Book of 0.32 may suggest asset coverage
- Price/Sales of 0.55 is below sector average
Watchpoints
- P/E and Forward P/E are negative, indicating no earnings
- No Graham Number or Intrinsic Value available
- Valuation multiples reflect distress, not value
Future
58/100
Ref Growth rates
Positives
- 21.3% YoY revenue growth
- Recent EPS YoY growth of +90.1%
- Improving earnings surprises and Q/Q EPS growth of +19.3%
Watchpoints
- No positive earnings trajectory established
- Forward P/E of -0.65 indicates continued losses
Past
20/100
Ref Historical trends
Positives
- Some quarters show strong earnings beats
Watchpoints
- Consistent history of large losses and negative EPS
- 5Y price change of -100.0%, indicating total value erosion
- Multiple quarters with large negative earnings surprises
Health
15/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Current ratio of 2.12 supports short-term obligations
- Quick ratio of 1.14 shows some liquid asset coverage
- Debt/Equity of 0.35 is conservative
Watchpoints
- Piotroski F-Score of 1/9 indicates near-collapse of financial health
- ROA of -19.31% and ROE of -78.22% show capital destruction
- No Altman Z-Score reported, but implied distress
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- Dividend strength score of 0/100
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$1.62
Analyst Target
$7.5
Upside/Downside
+363.0%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for BNGO and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
BNGO
Bionano Genomics, Inc.
Primary
|
-100.0% | -99.8% | -79.2% | -52.1% | +6.6% | +8.0% |
|
ALUR
Allurion Technologies Inc.
Peer
|
-99.5% | -99.5% | -63.8% | -55.6% | -3.6% | -27.6% |
|
BMGL
Basel Medical Group Ltd
Peer
|
-82.0% | -82.0% | -82.0% | -64.4% | +23.8% | -3.5% |
|
BFRI
Biofrontera Inc.
Peer
|
-98.9% | -94.6% | -7.4% | -5.7% | +38.9% | +20.1% |
|
BMRA
Biomerica, Inc.
Peer
|
-95.7% | -88.5% | -46.5% | -34.3% | -3.0% | 0.0% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
-0.65
PEG Ratio
N/A
P/B Ratio
0.32
P/S Ratio
0.55
EV/Revenue
0.42
EV/EBITDA
-0.75
Market Cap
$16.49M
Profitability
Profit margins and return metrics
Profit Margin
-134.36%
Operating Margin
-115.89%
Gross Margin
45.97%
ROE
-78.22%
ROA
-19.31%
Growth
Revenue and earnings growth rates
Revenue Growth
+21.3%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.35
Low debt
Current Ratio
2.12
Strong
Quick Ratio
1.14
Good
Cash/Share
$2.12
Quarterly Earnings History
EPS performance vs analyst estimates
2026-03-11
$N/A
2025-11-13
$-1.59
+32.0% surprise
2025-08-14
$-1.97
+34.0% surprise
2025-05-14
$-1.15
+62.0% surprise
Healthcare Sector Comparison
Comparing BNGO against 147 companies in the Healthcare sector
(10 bullish, 55 neutral, 82 bearish)
Return on Equity (ROE)
-78.22%
This Stock
vs
-52.77%
Sector Avg
+48.2%
(Excellent)
Profit Margin
-134.36%
This Stock
vs
-20.78%
Sector Avg
+546.7%
(Superior)
Debt to Equity
0.35
This Stock
vs
6.16
Sector Avg
-94.4%
(Less Debt)
Revenue Growth
21.3%
This Stock
vs
137.39%
Sector Avg
-84.5%
(Slower)
Current Ratio
2.12
This Stock
vs
3.36
Sector Avg
-36.8%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
BNGO
Bionano Genomics, Inc.
|
BEARISH | $16.49M | - | -78.2% | -134.4% | $1.62 | |
|
ALUR
Allurion Technologies Inc.
|
BEARISH | $16.47M | - | -% | -187.9% | $1.34 | |
|
BMGL
Basel Medical Group Ltd
|
BEARISH | $15.03M | - | -194.6% | -99.8% | $0.8 | |
|
BFRI
Biofrontera Inc.
|
BEARISH | $11.65M | - | -1191.7% | -47.3% | $1.0 | |
|
BMRA
Biomerica, Inc.
|
BEARISH | $7.76M | - | -84.3% | -90.3% | $2.57 |
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
2 analysts
HC Wainwright & Co.
2025-11-24
Buy
Buy
HC Wainwright & Co.
2025-08-18
Buy
Buy
Past News Coverage
Recent headlines mentioning BNGO from our newsroom.
Newest → oldest
No matching news yet.